Some drugs with co-insurance cuts have low usage, high denials
The lowered co-insurance rates on some average sales price (ASP) drugs in the 2nd quarter of 2023 is good news for some Part B drug users. But these modest cuts still represent only a small percentage of Medicare’s enormous drug tab.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.